Physician profile
Ivan E Laboy Ortiz
NPI 1245565696
$8,870.73
in general payments reported to CMS, 2019-2025
18 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,722 · 2020: $1,388 · 2021: $925 · 2022: $1,320 · 2023: $1,111 · 2024: $747 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,514.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,913.70 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $1,318.31 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,272.57 | 2019-2025 | Lokelma, Farxiga |
| Eli Lilly Export S.A. Puerto Rico Branch | $1,196.55 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $802.57 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $585.43 | 2019-2024 | Janumet, Steglatro, Januvia |
| Amgen INC. | $543.03 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $456.58 | 2019-2021 | |
| Abbott Laboratories | $334.08 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $102.99 | 2021-2022 | |
| Abbvie INC. | $95.42 | 2019-2023 | |
| Medtronic, INC. | $81.66 | 2019 | |
| Lilly USA, LLC | $42.54 | 2025 | Jardiance |
| Dexcom, INC. | $38.95 | 2022-2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $23.39 | 2023 | Hemlibra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.47 | 2023 | |
| Bayer Puerto Rico INC. | $22.47 | 2023 | Kerendia |
| Radius Health, INC. | $18.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Laboy Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.